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ABSTRACT 13 
Monoclonal antibodies (mAbs) and their related products as antibody-drug-conjugates (ADCs) or biosimilars 14 
represent a constantly growing class of molecules therapeutic proteins used as treatment against numerous 15 
diseases. These compounds can undergo several modifications which could alter the efficiency of treatments. 16 
In this context, several analytical methods were designed to deliver a comprehensive structural characteriza-17 
tion and guarantee the quality of biotherapeutics. Capillary electrophoresis (CE) is considered today as a ma-18 
jor technique for the analysis of biotherapeutics due to benefic characteristics as high resolution separation 19 
and miniaturized format. Different CE modes have been developed to characterize mAbs at different levels 20 
such as capillary gel electrophoresis (CGE), capillary isoelectric focusing (cIEF), and capillary zone electropho-21 
resis (CZE). Recent developments in CE-mass spectrometry (MS) coupling assessed this technology as a prom-22 
ising tool to obtain high level structural characterization of biopharmaceuticals. Moreover, upcoming tech-23 
niques such as 2D CE-MS and microfluidic systems are now emerging to offer new possibilities beyond actual 24 
limits. This review will be dedicated to discuss the state-of-the-art CE-based methods for the characterization 25 
of mAbs and ADCs in the period 2016-2018. 26 
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1. Introduction 39 
Today, more than 75 mAbs and ADCs are approved as therapeutic products by the European Medicines Agency 40 
(EMA) and the Food and Drug Administration (FDA) [1]. mAbs are occupying the top selling ranks for drugs since 41 
last decade [2, 3] making it one of the most successful category of product in the pharmaceutical industry. In 42 
addition, the approval of 16 new mAbs over the last couple of years suggests that expansion will further continue 43 
[4]. The current technologies to produce recombinant proteins enable to yield different types of biomolecules 44 
derived from the mAbs format such as antibody-drug conjugates (ADCs), fusion proteins, bispecific antibodies 45 
(bsAb) or biosimilars [5-7]. Their development is currently driven by the treatment of different diseases such as 46 
various cancers, infections, autoimmune disorders or to prevent transplant rejections.  47 
Due to their protein nature, these compounds are highly complex macromolecules with typical molecular mass 48 
of approximately 150 kDa. However, mAbs can undergo several chemical degradations, post-translational modi-49 
fications (PTMs) or 3D conformation alterations, which may lead to the inactivation of the drug or immune reac-50 
tions [8, 9]. These modifications increase the heterogeneity and the complexity of the protein. The characteriza-51 
tion and control of protein stability are therefore crucial aspects during each phase of mAbs development, from 52 
early-stage development to production, storage, and delivery. For assessment of mAbs and ADCs, regulation 53 
agencies have introduced the concept of critical quality attributes (CQA) which describes for each therapeutic 54 
protein, the PTMs potentially involved in the alteration of the pharmacokinetic (PK) and pharmacodynamic (PD) 55 
properties of the proteins[10, 11]. Thus, stringent analytical methods for comprehensive biotherapeutics charac-56 
terization are necessary to ensure the quality of this type of products. 57 
Hence, a large array of separation techniques in liquid phase like high performance liquid chromatography (HPLC) 58 
or capillary electrophoresis (CE) were developed for quality control of biopharmaceutics [12-15]. These comple-59 
mentary methods allow the separation of the main mAbs isoforms from the modified variants in order to provide 60 
a detailed characterization over the different level defining the structure of the protein. In the late 80’s, CE has 61 
emerged as a powerful technique to analyze biomolecules, thanks to the electromigration phenomenon and the 62 
possibility to use aqueous buffers that preserve the high-order structure of proteins [16, 17]. Consequently to the 63 
introduction of mAbs, CE has therefore demonstrated to be a relevant analytical separation for the characteriza-64 
tion and stability study of this category of protein especially due to the unique selectivity of the electrophoretic 65 
separation [14, 18, 19]. Different electrophoretic modes such as capillary gel electrophoresis (CGE), capillary iso-66 
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electric focusing (cIEF) and capillary zone electrophoresis (CZE) are commonly used to assess mAbs. CE experi-67 
ments are generally performed utilizing optical detection such as UV or fluorescence detector. However, in order 68 
to provide structural information, capillary electrophoresis hyphenated to mass spectrometry (CE-MS) has been 69 
extensively developed to overcome the limitations of optical detections. Different strategies like intact, middle-70 
up, middle-down and bottom-up analysis were established to access the amino acid sequence and the major 71 
PTMs of biotherapeutics [20-22]. Also, CE-MS has been recognized as a powerful tool for immunoglobulin G (IgG) 72 
glycan profiling and relative quantitation.  73 
Regardless, the constant introduction of novel mAbs alongside to innovative therapeutic proteins based on this 74 
format still maintains the urge to develop further adapted analytical methodologies. Especially, CE has continued 75 
to gain a growing interest from the scientific community. This review, following a previous work [14], is focusing 76 
on the latest developments regarding the application of CE-based techniques to characterize mAbs and ADCs in 77 
the period of 2016-2018. In addition, it provides some insights concerning the future developments for CE based 78 
analysis of mAbs and their related formats. 79 
2. Capillary Gel Electrophoresis (CGE) 80 
2.1. Technical considerations 81 
Based on the separation of macromolecules according to their size, CGE represents one of the reference meth-82 
ods to assess size heterogeneity and glycan profiling of mAbs and ADCs. Among CGE techniques, capillary electro-83 
phoresis-sodium dodecyl sulfate (CE-SDS) is the adaptation of the sodium dodecyl sulfate-polyacrylamide gel elec-84 
trophoresis (SDS-PAGE) methodology converted to a miniaturized capillary format. That miniaturization involves 85 
the replacement of the traditional slab gel by soluble polymers employed as a replaceable molecular sieve. It 86 
presents the advantages of short analysis time, to reduce the difficulty of handling, to decrease the amount of 87 
sample injected and improve the reproducibility. One major concern of this methodological transfer affecting the 88 
separation efficiency, consists of analyte adsorption phenomena in the inner capillary wall. To avoid this harmful 89 
phenomena, the development of adapted separation conditions was realized by increasing the concentration and 90 
the viscosity of the gel or the inclusion of additives to the BGE. A posivite consequence of the use of additives is 91 
the suppression of the electroosmotic flow (EOF). Nowadays, commercial sieving kits are available and widely 92 
used in the biopharmaceutical industry.  Nevertheless, other strategies have been described to reduce adsorption 93 
phenomena and EOF canceling, based particularly on the neutralization of the inner surface of the capillary by 94 
chemical reaction. Various commercial or home-made solutions have been reported in the literature as polyvinyl 95 
alcohol (PVA) [23] or linear polyacrylamide (LPA) [24], showing the significance of this modification to maintain a 96 
good reproducibility of separation.  97 
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Detection of analytes in CGE is classically achieved by optical techniques like UV absorption or fluorescence. In 98 
most cases, UV detection of proteins is programmed at 220 nm. However, 200, 214 and 280 nm are sometimes 99 
used depending on separation conditions. Laser-induced fluorescence (LIF) detection provides an higher sensitiv-100 
ity than classical UV. Generally, the excitation of analytes is performed at 488 nm and the emission signal is mon-101 
itored at 520 nm. Although, just a few molecules are naturally fluorescent which implies otherwise a derivatization 102 
step for the non-fluorescent analytes. Concerning the analysis of mAb glycosylations, chemical modification based 103 
on 8-Aminopyrene-1,3,6-trisulfonic-acid (APTS) reaction allows the derivation of fluorophoric group and the addi-104 
tion of three negative charges to the glycan moiety, which is considered today as one of the reference method 105 
[23, 25-28]. However recently, other dye reagents like 2-aminobenzoic acid (2-AA) (excitation: 325 nm emission: 106 
405 nm) [29] and Teal™ (excitation and emission: same as APTS) [28], providing respectively one and three nega-107 
tive charges, have been reported for glycan analysis. These methods revealed excellent precision and accuracy. 108 
Authors comment about the potential of detecting minor glycan species with Teal™ [28]. Moreover, the Teal™ is 109 
preferred for derivatization step because of (i) its higher reactivity, (ii) lower amount of derivatization compound 110 
required which contain salts, and (iii) therefore an improved MS compatibility as compared to the other common 111 
fluorescent dyes. It can also provide higher sensitivity detection and accurate identification of analytes for CGE-112 
LIF-MS experiments  113 
 114 
2.2. Applications 115 
CGE is commonly used for N-glycan, size heterogeneity, purity, stability and aggregation assessment of intact 116 
and reduced mAbs. ADCs are also characterized by CGE to estimate the drug-to-antibody ratio (DAR). CGE is com-117 
monly employed to evaluate the similarity between original glycoproteins and their biosimilar candidates. Table 1 118 
summarizes the applications of CGE for mAbs and ADCs characterization between 2016-2018. 119 
2.2.1. Size variants assessments 120 
Two strategies are established to study mAbs size heterogeneity: non-reduced and reduced conditions. Non-121 
reduced CE-SDS is classically used to control purity/aggregation whereas reduced CE-SDS is mostly used to study 122 
mAbs’ fragments. 123 
In 2016, Xie et al. described a method to analyze the level of reduced disulfide bonds of mAb using non-reduced 124 
CE-SDS [30]. They studied the impact of downshift cell culture pH on the formation of this modification. They 125 
observed a decrease in the level of reduced disulfide bond by 31 % when lowering pH from 6.95 to 6.75 after 6 126 
days incubation. In another study, Esterman et al. evaluated the system suitability acceptance criteria of the U.S. 127 
Pharmacopeia (USP) IgG standard using non-reducing CE-SDS and reducing CE-SDS. Two protocols originating from 128 
the USP and Bristol-Myers Squibb (BMS) were assessed [31]. Authors concluded that USP method is not suitable 129 
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for lot-release and stability testing of mAbs due to a high level of fragmentation under non-reducing conditions. 130 
In 2018, Schiel et al. analyzed the NISTmAb by non-reduced CE-SDS to assess purity, and reduced CE-SDS to eval-131 
uate the glycan occupancies of the heavy chain (HC) alongside to the relative abundances of non-reducible species 132 
[32]. Inter and intra-vial homogeneity was evaluated, and excellent standard deviation were calculated (0.053 for 133 
intra-vial and 0.0137 for inter-vial). Griaud et al. and Miao et al. reported two comprehensive studies using an 134 
array of orthogonal techniques and strategies including CE-SDS for biosimilarity assessment [33, 34]. They com-135 
pared the electropherograms of intact and reduced mAbs and their biosimilar candidate. Minor differences were 136 
observed but generally the candidate was very close to the originator.  137 
Fragmentation of mAbs represents a CQA that needs to be monitored in order to assess the purity and integrity 138 
during the life cycle of the product. Studies of the fragments from stressed mAbs can bring useful information 139 
notably to understand mechanism of mAbs degradation [35-37]. These investigations enable to improve mAbs 140 
production and storage conditions.  141 
In 2017, Dada et al. reported a characterization strategy that establishes the correlation between hinge region 142 
fragments analyzed by CE-SDS and size exclusion chromatography (SEC) [38]. Comparative assessment of frag-143 
ments by SEC, and CE-SDS showed similar correlation with incubation time. Authors analyzed collected fractions 144 
of stressed mAbs at different days. An increase of HC, HC-HC aggregates (HH) and HC-HC-LC aggregates (HHL) were 145 
observed during incubation. Kubota et al. described a CGE method to identify and characterize an impurity of 10 146 
kDa formed after incubation of sample at 25°C for 6 months [35] (Figure 1). In-gel digestion peptide mapping 147 
followed by reverse phase liquid chromatography-mass spectrometry (RPLC-MS) and Gelfree 8100 fractionation 148 
were used to identify the impurity corresponding to the HC1-104 fragment which is involved in the complemen-149 
tary determining region (CDR). In 2017 , Li et al. studied the fragments of an IgG1 obtained by forced degradation 150 
at 40°C for 28 days. Two unique fragments were discovered when CE-SDS was employed for the purity analysis of 151 
mAbs [36]. Then, these two fragments were fully analyzed and identified to be generated by a Ser105-Ser106 152 
peptide bond cleavage at CDR3 of the HC using different HPLC–MS strategies.  153 
In the 90’s, microfluidic transposition of capillary electrophoresis was developed to achieve fast separation for 154 
characterization, development, release, and stability testing of therapeutics. Especialy, miniaturization of CGE 155 
(mGE) was of great interest for mAbs analysis. Indeed, microchips, due to their intrinsic properties, enable to 156 
perform high-throughput analysis while maintaining resolution and efficiency. This device is increasingly recog-157 
nized as a valuable alternative to conventional CE. In 2016, Cai et al. optimized mGE to study mAbs in denaturing 158 
conditions [39]. The percentage of SDS was investigated to obtain totally degraded mAb. Three IgG1 and five IgG4 159 
were studied. The reduced mAbs were analyzed by mGE. Electropherograms showed baseline separated peaks of 160 
light chains (LC) and HC obtained in less than 30 s. The method could be successfully qualified. The authors demon-161 
strated the precision and the specificity with a linear range of 16-3000 µg/mL and a LOQ of 7.8 µg/mL. Comparison 162 
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between mGE and conventional CE-SDS showed that the main difference is the analysis time. Both methods pro-163 
vided similar performances in terms of separation efficiency. However, they noticed that mGE is slightly less sen-164 
sitive that CE-SDS. In 2017, Smith et al. validated a mGE method to study biopharmaceuticals size variants and 165 
purity in reducing and non-reducing conditions [40]. Specificity, linearity, accuracy, repeatability, reproducibility, 166 
limit of detection/quantification (LOD/LOQ) and robustness were assessed, and results confirmed the excellent 167 
features of mGE for reduced and non-reduced mAb analysis. 168 
Concerning the characterization of ADCs, critical information regarding the nature of aggregates and/or frag-169 
ments can be provided by CE-SDS following different modes of sample preparation as reduced or non-reduced. 170 
Nevertheless, this method is more limited for the analysis of ADCs depending of the conjugation chemistry and 171 
the attachment sites as lysines, cysteines or glycans [41-44]. Concerning lysine-conjugated ADCs, in 2016, Chen 172 
and co-workers published non-reducing CE-SDS reports of trastuzumab emtansine (T-DM1) and the unconjugated 173 
trastuzumab. Comparable electropherograms with a main peak corresponding to the full-length antibody and mi-174 
nor peaks representing lower and higher molecular weight species (LMW and HMW) were observed using CE-SDS 175 
analysis [42]. The same year, in-depth structural characterization of T-DM1 and its biosimilar candidate were in-176 
vestigated using several orthogonal analytical methods [45]. Characterization of size variants performed with the 177 
combination of SEC and CE-SDS exhibited predominant monomer contents (>95 %) in T-DM1 and the biosimilar 178 
ADC sample indicating their similarity in the aspect of size heterogeneity. In 2018, Wagh et al. reported a compre-179 
hensive study in another lysine-conjugated ADCs [43]. Analysis of lysine-conjugated ADCs by non-reducing CE-SDS 180 
confirmed a main peak of full-length conjugated antibody and few minor peaks corresponding to LMW and HMW. 181 
With reduced CE-SDS, results showed prominent peaks corresponding to HC and LC and minor peaks partially 182 
separated for LC with 0 to 2 drug load. 183 
Concerning the interchain-cysteine modified ADCs, CE-SDS profiles look totally different as compared to lysine-184 
conjugated ADCs. Indeed, the conjugation of the cytotoxic drugs to antibodies is performed through cysteine sul-185 
fide groups which are activated by a partial reduction of interchain disulfide bonds. It means that some antibody 186 
chains are no longer covalently linked by intact disulfide bonds. The presence of SDS in the sample implied the 187 
formation of protein-SDS complexes and the breaking of non-covalent interactions. This involves the dissociation 188 
of any antibody chains depending on the position and the number of cytotoxic drugs which then causes the pres-189 
ence of low molecular masses ADCs fragments.  190 
 191 
2.2.2. Glycan analysis 192 
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N-glycan represents a CQA for biopharmaceutical as it can compromise the efficiency and the safety of mAbs. 193 
O’Flaherty et al., Zhang et al. and Hajba et al. reviewed HPLC, CE and MS methods for glycan analysis from mono-194 
saccharides level to intact proteins including O-glycans and N-glycans until 2016 [46-48]. N-linked carbohydrates 195 
profiling and quantitation are carried out by CGE. Before analysis, the carbohydrates are first  released from mAbs 196 
using specific endoglycosidases. Then, glycans are derivatized with a fluorescent dye. Afterwards, labelled glycans 197 
are analyzed by CGE-LIF. For the analysis of glycans, some polymers are present in the buffer, but the separation 198 
of glycan is not based on a sieving mechanism. The polymer is used to suppress adsorption phenomena and in-199 
crease separation efficiency [49].  200 
In 2016 Kovacs et al. reported a high-throughput N-glycan analysis by CGE-LIF with APTS labeled glycans [25]. 201 
Using a method named separation window dependent multiple injection (SWDMI)  they were able to analyze 96 202 
samples in 4h instead of 12h for individual separation cycle. The glycan release step has also been shortened. 203 
Szigeti et al. developed microcolumns with immobilized PNGase F which carry out rapid and easy to automate N-204 
glycan release [26]. This setup allowed them to perform efficient and reproducible deglycosylation of mAb in less 205 
than 10 min. More recently, Szarka et al. evaluated proton beam irradiation on IgG N-glycan to anticipate the effect 206 
of a long space travel [50]. After analysis of labeled glycan by CGE-LIF, they concluded that changes occur only 207 
above 10 000 Gy which is quite inferior to Galactic Cosmic Ray and Solar Particle Events. Kubo et al. reported a 208 
new polyethyleneglycol dimethacrylate (PEGDMA) coating [51]. Different conditions for polymerization procedure 209 
were optimized. They showed the effective separation of sugars released from mAbs using this coating. Authors 210 
suggested that the concentration and ethylene oxide units of PEGDMA affected the range of separable molecular 211 
weight. 212 
   In 2018, Chen et al. reported the use of CGE-LIF as an orthogonal method to confirm the N-glycan quantitative 213 
results obtained by miniaturized CE-MS (mCE-MS) [27]. A DNA analyzer was used for CGE-LIF experiment. Similar 214 
results, in terms of quantitation and resolution were obtained but mCE-MS provided faster separation. Quantita-215 
tion of glycans has been successfully done by Szigeti et al. [52] over an extended concentration range. In this work, 216 
quantitation of Man5 on adalimumab has been investigated. They obtained an excellent (R²=0.9995) between 217 
peak area of Man5 and concentration within a range 0.01-0.5 ng/µL. Authors suggested this quantitation method 218 
could be easily applied to other carbohydrates moieties. To further improve the identification of glycosylation 219 
patterns, CE-LIF-MS coupling has been developed by Khan et al. [28]. This setup allowed the authors to quantify 220 
and identify N-glycans of NISTmAb (Figure 2). The novel fluorescent dye used is Teal™ which is MS compatible and 221 
provides a higher quantum yield than classic APTS.  This derivative agent permits to reach qualitative and quanti-222 
tative sugars information. Results of the baseline separations of different N-glycans showed excellent correlation 223 
between LIF and MS. 224 
 225 
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3. Capillary Isoelectric focusing (cIEF) and imagedcIEF (icIEF) 226 
3.1. Technical considerations 227 
cIEF represents one of the most resolutive methods to separate proteins depending on their isoelectric point 228 
(pI) [53].  cIEF is the well-known miniaturized analogue of IEF slab gel mainly described for the analysis of charge 229 
heterogeneity of mAbs and ADCs [54-58]. Historically, the conventional protocol of cIEF follows a two steps pro-230 
cedure starting by a focusing then a mobilization step. Briefly, cIEF experiment is performed by using a alkaline 231 
catholyte (NaOH) and an acid anolyte (H3PO4). The capillary is filled with a solution containing carrier ampholytes 232 
and analytes. By applying a high voltage, a gradient of pH is established through the whole capillary and proteins 233 
are focusing in the capillary until they reach their own pI. At this point, the mobility of proteins is near zero because 234 
their apparent charge is neutral. Then, sample is forced to migrate toward the detector, which is placed close to 235 
the capillary exit using an electrophoretic or hydrodynamic mobilization step. However, the mobilization step can 236 
induce some undesired effects like a decrease of resolution or modification of migration time. To address these 237 
drawbacks, whole-column imaging cIEF (icIEF) has been developed. In icIEF experiments, UV-detection is per-238 
formed by a charge coupled device (CCD) camera all along the capillary (5cm) allowing to cancel the mobilization 239 
step and achieve faster separation with greater resolution, better reproducibility and reduced sample volume. 240 
Commonly to cIEF and icIEF experiments, coating of inner surface capillaries is mandatory to eliminate EOF and 241 
improve separation efficiency. For this purpose, neutral capillaries using dynamic or permanent coating have been 242 
implemented. In cIEF, the most described coatings are LPA [54, 57, 59], hydroxypropyl methylcellulose (HPMC) 243 
[60, 61] and PVA [62]. Concerning icIEF, a majority of reports in the literature described the use of a fluorocarbon 244 
capillary due to manufacturer’s near monopoly (Proteinsimple) [55, 63-65]. However, other manufacturer like 245 
CEInfinite provide icIEF system allowing the use of a wider choice of coated capillary solution. 246 
Over the last couple of years, the technical advances of cIEF and icIEF detection modes have been mainly 247 
achieved using coupling with MS. Indeed, concerning UV-detection, almost every application described in cIEF and 248 
icIEF are performed at 280 nm due to good absorption of proteins at this wavelength and the strong absorbance 249 
of ampholytes at lower wavelengths. MS detection represents a key feature for future developments to improve 250 
the performance of cIEF and icIEF in terms of sensitivity and structural characterization [66-68]. However, devel-251 
opment of the hyphenation between cIEF and MS is curbed by technical issues such as presence of salts and 252 
ampholytes. Very recently, different strategies of cIEF-MS and icIEF-MS coupling have been described in order to 253 
reduce or eliminate these adverse effects. In 2017, Huhner et al. developed an cIEF-MS methodology using an 254 
innovative two dimensional CE-MS instrumentation allowing to perform cIEF or icIEF separation in the first dimen-255 
sion followed by CZE in the second dimension, with online coupling to high-resolution MS [69, 70]. In 2018, Dai et 256 
al. described a new automated cIEF-MS method to separate mAb charge variants using an electrokinetically 257 
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pumped sheath liquid nanospray CE-MS technology [67]. These last developments showed the potential of cIEF-258 
MS coupling to become a method of interest in biopharmaceutical industries and will be deeply discussed in the 259 
section 5.  260 
 261 
3.2. Applications 262 
cIEF and icIEF play important roles in the characterization of purity and isoelectric point (pI) of mAbs. These 263 
methodologies are considered as reference methods to determine mAbs charge heterogeneity. Several reports 264 
described these techniques for the period until 2016 [14, 15, 37, 71]. In recent years, new enzymatic digestion, 265 
new matrix and fractionation method were reported. Table 1 displays cIEF and icIEF applications for mAbs analysis 266 
in 2016-2018.  267 
Several inter-laboratory studies to evaluate the robustness of cIEF and icIEF have been detailed these last dec-268 
ades [57, 58]. The most recent in 2018, described by Wu et al., reported an interlaboratory method validation of 269 
icIEF for mAbs charge heterogeneity analysis [72]. 10 laboratories and 8 companies were involved.  icIEF protocol 270 
was performed according to the international conference on harmonization (ICH) guidelines. The method was 271 
evaluated on four mAbs. Results confirmed the good precision in pI determination, the satisfying separation of 272 
charge variants and the high precision for suitable assessment of purity. Following icIEF method, the pIs and the 273 
charge variants of 23 therapeutic mAbs have been reported by Goyon et al.[73]. Experimental pIs, determined by 274 
icIEF, were ranged between 6.1 and 9.4. Theoretical and measured pIs were compared giving absolute deviations 275 
always lower than 15%. The relative distributions of acidic and basic variants were also determined to range be-276 
tween 15 to 30 % using both cation exchange chromatography (CEX) and icIEF which was in agreement with the 277 
literature. King et al. analyzed an IgG1 by hydrophobic interaction chromatography (HIC) and obtained good sep-278 
aration of two peaks [74]. The two peaks were isolated and further characterized by HPLC-MS and icIEF using 279 
different enzymatic strategies. pI of 7.6 and 7.8 were respectively found for these peaks. Deamidation of an as-280 
paragine (deaN) residue, located in the light chain CDR3, has been highlighted. They also showed the negative 281 
impact of this PTM for the antigen binding affinity of the mAb. Finally, influence of pH on the deamidation for-282 
mation was studied. The results confirmed an increasing amount of deamidation at slightly basic pH. 283 
cIEF and icIEF are extensively used to study fragments from degraded mAbs and biosimilarity assessment. Xie et 284 
al. studied the effect of pH shift on the production of IgG1 mAb in Chinese hamster ovary cells [30]. The pI and 285 
absolute percentages of acidic, main and basic variants were determined by cIEF. They concluded that a pH down-286 
shift reduces the amount of acidic variants and then prevents the formation of PTMs. Further investigations 287 
through tryptic peptide mapping using MS highlighted that deamination proportion of HC-Asn388 and HC-Asn394 288 
or HC-Asn393 decreases while pH is lowered. In the same year, Zhang et al. developed a icIEF to analyze mAb 289 
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fragments yielded by an optimized SpeB digestion (cysteine protease) [75]. With this new strategy, they obtained 290 
well resolved peaks of LC, Fd, Fc/2 fragments and their PTMs. They also carried out a study of degraded mAbs and 291 
they evaluated the biosimilarity of rituximab and a candidate with SpeB proteolysis. Authors demonstrated the 292 
partial removal of C-terminal lysine between the reference and the biosimilar rituximab as well as a lower level of 293 
deamidation. The same year, biosimilarity assessment studies on Avastin (bevacizumab) has been reported by 294 
Zhao et al. [76]. Several analytical methods, including icIEF, were used to compare pharmacokinetics properties of 295 
Avastin and a biosimilar (Figure 3). Firstly, mAbs were prepared to obtain isolated acidic, basic and main variants. 296 
Then, these fragments were analyzed by different HPLC and CE techniques. Results showed no significant differ-297 
ences in pharmacokinetics parameters. In-depth study of the biosimilarity of tocilizumab candidate was per-298 
formed by Miao et al. [34]. Using different methods such as icIEF, CEX, SEC and RPLC-MS to determine biological 299 
and physicochemical characterization, authors illustrated the very high similarity of the biosimilar and the origi-300 
nator tocilizumab. 301 
Classic denaturant like urea or formamide, used in icIEF to stabilize the molecule charge can sometimes deteri-302 
orate proteins by aggregation process. Thus, a novel matrix formula for icIEF experiment in native conditions was 303 
explored and optimized by Zhang et al. to study charge heterogeneity of proteins [77]. This matrix, composed by 304 
non-detergent sulfobetaine and taurine (NDSB-T) possesses the stabilization and separation power while main-305 
taining protein integrity. NDSB-T can separate and quantify protein charge species in native state and therefore 306 
avoid partial denaturation. This matrix enables to improve the assay robustness, repeatability, precision, accuracy 307 
and peak resolution for an aggregation-prone mAb. Another issue for cIEF analysis is the relatively low amount of 308 
sample injected which does not permit the fractionation of variants for further characterization. Hosken et al. 309 
proposed an optimized preparative IEF based technique which allows fractionating the charge variants of intact 310 
mAb [78]. They carried out an isoelectric focusing using a free-flow electrophoresis (FFE). FFE consists  of two 311 
plates between a carrier ampholyte enabling the focusing of charge variants when a high voltage is applied. High 312 
amount of sample can be injected and then the isolation of acidic, basic and main variants becomes possible. This 313 
method was applied on 3 mAbs. Charge variants of two mAbs were highly enriched except for the variants of the 314 
mAb with the highest pI which did not focus enough. The enriched fractions were sufficient for physico-chemical 315 
and biological characterization and many PTMs were identified. Using another strategy, developers from CEinfinite 316 
proposed new methodologies for icIEF coupled to MS and/or peak fractionation. They developed a specific pro-317 
prietary cartridge specially designed for high performance preparative icIEF using a 200 µm ID capillary followed 318 
by a 50 µm ID transfer capillary. This geometry allowed great flexibility such as protein fractionation enabling direct 319 
spotting process to MALDI target plate.  320 
In 2018, Turner et al. optimized cIEF method for NISTmAb qualification [79]. Separation of basic variants, main 321 
peak and acidic variants has been performed and C-terminal lysine has been identified. The authors also realized 322 
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the titration of each variant in a range from 0.1 to 0.6 mg/mL with R² > 0.98 and RSD < 8%. A comparison with an 323 
optimized CZE method allowed authors to confirm that cIEF assay is a valuable characterization tool which affords 324 
information about charge variant apparent pI while CZE assay was found to be suitable for qualification as a routine 325 
quality monitoring assay.  326 
Focusing on ADCs analysis, isoelectric focusing methods may give significantly different information on electro-327 
phoretic profiles of ADCs [41, 42, 44]. The nature of the drug-linker, especially the charge that can be added to the 328 
ADC represents a major concern on the charge profile of the protein. For example, Ji et al. described the charac-329 
terization of thio-succinimide hydrolysis of monomethyl auristatin E (vc-MMAE) ADC using icIEF during the formu-330 
lation development [80]. As uncharged vc-MMAE conjugation through sulfhydryl groups in the interchain-cysteine 331 
residues is known not to change the net charge of the ADCs, similar charge variant profiles were expected between 332 
the conjugated and the unconjugated mAb. However, overlay of icIEF vc-MMAE ADC’s profiles, incubated at pH 9 333 
during 0 to 48 hours, showed an important heterogeneity in the acidic region due to various negative charges of 334 
the ADC gained from both deamidation and succinimide hydrolysis of the thio-succinimide linker [80]. Concerning 335 
lysine-linked ADC, this type of chemistry eliminates basic sites in the proteins and changes ADCs pIs [81]. Lin et al. 336 
described the determination of mAb-Drug Maytansinoid 4 (DM4) with an average DAR of 3.6 by icIEF [81]. pI of 337 
the drug loaded species shifted toward acidic variants from the unconjugated mAb due to the increase in the 338 
number of DM4 drugs conjugated. More recently, Luo et al. confirmed these results performing the structural 339 
characterization of a mAb-DM1 ADCs using the combination of UV/vis spectroscopy, HPLC/TOF-MS and icIEF ana-340 
lytical methods [82]. Average DAR value (3.2) measured with icIEF was in good agreement with UV/vis and intact 341 
mass values (3.3 and 3.1 respectively). In 2018, Wagh et al. reported that icIEF can be applied to measure the level 342 
of unconjugated antibody and drug load distribution, but it cannot distinguish between conjugates, process inter-343 
mediates and impurities such as antibody with linker only and antibody with linker/drug conjugates. Indeed, con-344 
jugation of linker only and linker/with drug bring the same shift charge toward acidic, and therefore cannot be 345 
distinguished by icIEF. [43]. 346 
 347 
4. Capillary Zone Electrophoresis (CZE) 348 
4.1. Technical considerations 349 
Until the first development of CZE theory, this electrophoretic mode is still the most popular for CE applications. 350 
This technique leans on a separation of analytes in a background electrolyte (BGE) under an electrical field accord-351 
ing to their charge-to-size ratio [16]. Typically, the capillary is filled up with the BGE. After a sample loading in the 352 
capillary via a hydrodynamic or an electrokinetic injection, a separation voltage is applied to permit the migration 353 
of analytes into the capillary. The most widespread detection mode is UV detection using a single wavelength 354 
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detection (usually 214 nm) or a diode array detection. Besides UV, other modes are used in CZE as LIF and more 355 
recently MS. CZE-MS coupling requires some optimizations of separation conditions because of the weak toler-356 
ance to salts and the need of volatile solvents. Once these parameters laid down, MS detection enhances struc-357 
tural characterization of the samples. A complete section about the CE-MS coupling will be dedicated in the sec-358 
tion 5 of this review. 359 
Concerning the characterization of mAbs and ADCs, as CE-SDS and cIEF modes, the main issue of the CZE tech-360 
nique was the protein adsorption on the capillary wall. Especially for middle-up and intact mAbs analysis, dynamic 361 
or permanent chemical modification of the inner surface of the capillary must be performed prior to CZE separa-362 
tion. The majority of detailed protocols in the literature concerns the use of a dynamic HPMC coated capillary 363 
which is considered as a reference for mAb charge variants analysis [14, 83, 84]. However, different strategies have 364 
already been described with other dynamic positive coating as Polybrene [85] or neutral coating as polyethylene 365 
oxide [86, 87]. More recently, in 2017, Xiao et al. have developed an innovative coating inspired by a well-known 366 
biological phenomenon, the blood coagulation, and worked on a fibrin coating on an open tubular column [88]. 367 
Apart from this parameter, the optimization of experimental conditions concerning the mAb analysis in CZE de-368 
pends enormously on the physicochemical properties of the mAbs to characterize them at the desired levels and 369 
will be described in the application section 4.2.  370 
 371 
4.2. Applications 372 
4.2.1. Bottom-up analysis 373 
At the bottom-up level, major concerns regarding mAbs characterization such as glycoprofiling, isomerizations 374 
and amino-acid modifications, have been solved with CZE methods. Feng et al. have highlighted the N-glycosyla-375 
tion of two human IgGs with a comparison of CZE and micellar electrokinetic capillary chromatography (MEKC) 376 
[23]. They worked on a PVA coated capillary to obtain a separation of 26 glycoforms referenced in the national 377 
institute for bioprocessing research and training (NIBRT) glycobase in 17 minutes in CZE and 24 min in MEKC. They 378 
confirmed their results with additional tests combining α-fucosidase, α-neuraminidase and ß-galactosidase. To 379 
further improve mAbs characterization, Griaud’s team studied ranibizumab (Lucentis®) and a biosimilar 380 
(razumab®) by SEC, CE-SDS and CZE methods. After optimization, they separated and identified multiple serine to 381 
asparagine sequence variation sites on the mAbs. They checked the results with a MS detection and exposed a 382 
difference of 27.01 Da (6-9 %). The analysis of MS/MS spectra confirmed serine to asparagine substitution on the 383 
light chains [33]. The same year, disulfide isomers were separated with a high resolution. The study was focused 384 
on the development of an ultra-high voltage capillary electrophoresis (UHVCE) and the analysis of 3 mAbs and 1 385 
ADC. The analysis has been made with a 120 kV electric field (2 kV/cm) in a HPMC coated capillary. This system 386 
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enhanced resolution and separation speed allowing distinction of disulfide isomers [89]. More recently, CZE has 387 
also been developed to get the best repeatability in particular with one of the key source of differentiability of 388 
digestion. An integrated micro reactor has been set up to perform an in-line tryptic digestion to enhance the 389 
quality control of mAbs. After an off-line optimization step of enzyme concentration and incubation time, other 390 
major parameters have been adjusted in-line to determine the best nature of BGE (ionic strength, pH). The feasi-391 
bility and robustness of the project have been evaluated on three commercial mAbs: trastuzumab (Hercpetin®), 392 
infliximab (Remicade®) and tocilizumab (Roactemra®). The diffusion mediated proteolysis combined with an elec-393 
trophoretic separation (D-PES) has been developed on a polyethyleneoxide (PEO) coated capillary regenerated 394 
before each analysis. A specific injection pattern of mAb, trypsin and proteolytic buffer has been elaborated al-395 
lowing to produce a digest with the same efficiency as compared to the off-line protocol. This totally automated 396 
method is clearly a promising solution decreasing the total analysis time by a factor of four (5 hours needed to 397 
digest, separate and analyze a sample), decreasing the volume of reactants by 1000 fold and offering a great re-398 
peatability of the total ion electropherograms (TIE) [90].  399 
 400 
4.2.2. Intact analysis 401 
One of the highest challenges of separation methods dwells in intact proteins analysis. While CZE is not consid-402 
ered as a reference method so far, the development of this approach showed significant advances for mAb charge 403 
variants analysis. Today, a classical CZE protocol from the pioneer works of He et al. [91, 92] which is evaluated by 404 
an interlaboratory study [93], can be described as the use of a BGE composed of ε-aminocaproic acid (EACA), 405 
triethylenetetramine (TETA) and HPMC. In 2017, a complete tutorial about a quite similar protocol, has been pub-406 
lished in video format illustrated the separation of mAbs’ isoforms on a neutral capillary. These favorable condi-407 
tions increase efficiency, accuracy and repeatability while keeping undamaged capillary up to 150 injections [94]. 408 
Illustrating complexity to optimize the large number of parameters, Suba et al. described a “two-phase-four-step” 409 
approach allowing a rapid, iterative method development process for CZE [95].  Based on fluorocarbon coated 410 
capillaries, they set up a fast screening phase to adjust the pH and the ionic strength with the aim to get optimal 411 
migration time, stability and resolving capacity of the method. Then, a fine tuning phase leaned on the addition 412 
of TETA to enhance the viscosity and improve the peak resolving and the stability of the method. They concluded 413 
that optimal conditions were 50 mM EACA at pH 5.1 with 1 mM TETA and 0.05% v/v HPMC. The same year, Zhao 414 
et al. detailed the characterization of a biosimilar from Bevacizumab (Avastin®) using different methods as SEC, 415 
icIEF, CEX and CZE [96]. They indicated a purity of the acidic, basic and main peaks respectively of 94 %, 82 % and 416 
85 %. In addition, PK of this candidate has been studied showing that all the results are acceptable to validate it 417 
as a biosimilar. However, PK and purity are not the only parameters required to allow the commercialization of 418 
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this kind of molecules. Additional tests with other analytical methods need to be employed to enable the charac-419 
terization at different levels. Moritz et al. described a design of experiments (DoE) based on differences between 420 
the net charge and the hydrodynamic radius to optimize charge heterogeneity tests [97]. The DoE set up during 421 
this study highlighted important parameters for CZE optimization. Described work is promising for a successful 422 
development of CZE as a major method for biopharmaceuticals analysis. Alternative approach consisting of ex-423 
ploring new BGE conditions for mAb charge variants separation, has also been developed by Goyon et al. in 2018 424 
[87]. 17 marketed mAbs have been evaluated using solely a Bis-Tris buffer (pH 7.0) and PEO dynamic coating. 425 
Goyon et al. obtained a RSD < 5 % of migration times and the separation of acidic charge variants of 10 / 17 mAbs. 426 
They also compared their methodology with the reference CZE method involving EACA, TETA and HPMC. The novel 427 
CZE approach allowed separating additional charge variants (in particular more acidic variants). Conversely, a 428 
higher number of basic variants were separated by the reference CZE approach for two mAbs out of 17, demon-429 
strating the complementarity of the two approaches. The relative quantitation of acidic and basic variants has 430 
been established specifically 15-30 % of acidic variants and 5-15 % of basic variants (Figure 4). Authors concluded 431 
that their method used to separate native mAbs offers complementary results but extend five folds the analysis 432 
time and elicits a loss of sensitivity.  The same year, Kahle et al. realized a comparison of protein charge variants 433 
separated by CZE and cIEF to upgrade the quality control of batches [59]. Another approach on the development 434 
of innovative coating was performed by Xiao et al. They reported an easy-to-use coating which gave a good sepa-435 
ration of cetuximab (Erbitux®) and rituximab (Mabthera®) with respectively nine and five separated variants [88]. 436 
By contrast, in a bovine serum albumin (BSA) coated column, they distinguished seven and four variants for the 437 
same molecules. These separations were detected by UV detection at 280 nm and gave a satisfying repeatability 438 
with a deviation times < 2.42 % on day to day and run to run batches.  439 
To assess the robustness and the reproducibility of CZE methods, Kubota et al. proposed a validation study of 440 
CZE method for evaluating mAbs and ADCs [84]. Among the numerous tested parameters in this study, are repre-441 
sented identity, purity, specificity, linearity, precision, quantitation limit, repeatability, accuracy, range and robust-442 
ness of CZE to characterize biopharmaceuticals. 11 samples including 2 ADCs and 9 mAbs have been evaluated in 443 
this study with different pI, DAR, and structures. The method showed quantitative results with high specificity, 444 
separation efficiency and precision. Authors concluded that CZE appears to be a promising alternative to IEF and 445 
CEX. The nearest validation step has been established by Schiel et al. in 2018. In two separate studies, they inves-446 
tigated the reference material (RM 8671) called NIST mAb which is a first-of-kind reference material to inform on 447 
specific attributes during therapeutic proteins characterization [32, 79]. The identity, quality, stability of the NIST 448 
mAb have been studied. The CZE assay was found to be suitable for qualification as a routine quality monitoring 449 
assay due to excellent sensitivity, speed, simplicity, specificity, and intermediate precision. Based on their results, 450 
CZE was selected for longitudinal quality monitoring of the NISTmAb Reference Material charge heterogeneity. 451 
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 452 
 453 
5. Capillary electrophoresis – mass spectrometry (CE-MS) 454 
5.1. Technical considerations 455 
The growing need of precise characterization of biotherapeutics implies the constant evolution in separation 456 
methods especially with the achievement of additional structural information. As the performance of mass spec-457 
trometers improved in term of sensitivity, mass accuracy and scanning frequencies, MS became a key instrumen-458 
tation for the analysis of biomolecules. The complexity due to the large scale of heterogeneity on mAbs needs to 459 
take the sensitivity into account to characterize low amount isoforms. While the different miniaturized electro-460 
phoretic modes (CE-SDS, cIEF, CZE) coupled with spectrophotometric detection are already known to be reference 461 
methods for mAbs characterization, the main improvements developed these last few years were achieved in the 462 
development of CE-MS methods. Since the end of the eighties, instrumental developments have been constantly 463 
performed in order to optimized the hyphenation of CE with MS detection using offline or online approaches 464 
depending on the nature of the MS sources: electrospray ionization (ESI) and matrix assisted laser desorption 465 
ionization (MALDI) [98]. CE-MS coupling is usually implemented with ESI; however, specific CE-MALDI-MS applica-466 
tions were also described in the literature [99-101]. As the weak acceptance of salts and the need of volatile 467 
solvents is known to be primary parameters for CE-MS applications, one of the main issue for CE-MS instrumen-468 
tation is known to conserve a continuous electric field during CE separation while maintaining a stable spray. This 469 
last decades, a way to get around this issue has been to design innovative CE-MS interface geometries. Historical 470 
developed CE-MS interfacing systems relied on a conductive sheath-liquid, connected to the outlet electrode of 471 
the CE system, continuously injected to maintain the electrical field [102]. Despite a good robustness and an easy 472 
setup, regarding the very low amount of sample carried in the separation capillary, the dilution effect due to the 473 
sheath-liquid has a negative impact on MS sensitifity. To address this limitation, other geometries have been de-474 
veloped allowing to reduce to the minimum the flow rate or to wholly eliminate the sheath-liquid. Today some 475 
commercial CE-MS solutions based on sheath liquid and sheathless interface are already fully described in the 476 
literature and commercially available [98]. Nevertheless, regarding direct CE-ESI-MS, the main hurdle quite in com-477 
mon of all papers detailed in the literature consisted of the incompatibility of classical well known BGEs with MS 478 
detection due to the presence of nonvolatile compounds that diminishes drastically the quality of MS data. While 479 
some very recent articles describing improvement of CZE-ESI-MS or cIEF-ESI-MS applications for mAbs charge var-480 
iants characterization [67, 103, 104], another recent approach have been developed to reduce BGE impact on CE-481 
ESI-MS detection. Inspired by 2D LC-MS, the group of Prof. Neusüβ worked on a promising 2D CE-MS setup, pur-482 
suing to provide interference-free mass spectra with electrophoretic separations [105]. This advanced separation 483 
technique includes a first dimension which allows to perform a high resolving CE separation with nonvolatile BGEs 484 
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followed by a second dimension able to fully remove the ESI-interfering components from the analytes prior to 485 
MS detection. For this purpose, a mechanical four-port valve with a small volume loop was utilized to lead the 486 
analytes from the first dimension to the second one with limited diffusion. The main advantage of this approach 487 
is the possibility to perform the 1st dimension in any CE mode (CZE, cIEF, CE-SDS) with classical conditions discussed 488 
in previous sections (BGE, coating, additives, etc.). This type of instrumentation has the potential to further in-489 
crease the level of characterization achieved in a single experiment, but still needs some technical improvements 490 
to make it robust and get a marketed solution.  491 
 492 
5.2. Applications 493 
5.2.1. Amino acid sequence characterization 494 
MAbs are produced from a biosynthesis process in culture cells from living organisms that could induce some 495 
minor differences in the amino acid sequence or PTMs during the maturation phase of the proteins. Moreover, 496 
production, packaging and storage conditions of the molecules can also induce some amino acid substitutions or 497 
other sort of modifications. Since 2006, Gennaro et al. demonstrated the potential of CZE-ESI-MS to obtained the 498 
complete characterization of mAbs using a Lys-C digestion combined with HPLC-MS analysis [106]. In 2013, Ga-499 
houal et al. confirmed the positive impact of sheathless CZE-ESI-MS methods demonstrating the consistent char-500 
acterization of the amino acid sequence with 100% coverage and some PTMs such as N-glycosylations, N-terminal 501 
glutamic acid cyclization, asparagine deamidations (deaN), methionine oxidations (oxyM), and aspartic acid isom-502 
erization (isoD) in a single analysis [107, 108]. In 2016, Said et al. adapted the CZE-ESI-MS method, especially with 503 
the optimization of the tryptic digestion protocol, for the characterization of the primary structure of a cysteine-504 
linked ADC. Results revealed the method ability to characterize ADCs primary structure particularly with the loca-505 
tion of drug loaded peptides and the estimation of their conjugation level [109]. More recently, some aque-506 
ous/aprotic dipolar solvent mixes systems were tested by Dada et al. to enhance the peptide mapping on mAbs 507 
and ADCs. Authors explained that N,N-dimethylacetamide (DMA) and N,N-dimethylformamide (DMF) used as BGE 508 
allow to have a complete sequence coverage and improve the separation of peptides with a neutral coated capil-509 
lary at the expense of time analysis [110]. The results confirmed several advantages of CZE-ESI-MS for the analysis 510 
of small hydrophilic di-/tripeptides, large hydrophobic peptides, glycopeptides, and hydrophobic drug-linked pep-511 
tides.  512 
 513 
5.2.2. Glycosylation characterization 514 
Glycosylation is a PTM that occurs naturally during excretion of antibodies from the expression system to the 515 
extracellular medium. It only represents 2–5% of the total mass of the protein but it is subjected to extensive 516 
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studies due to its significant influence on effector functions of mAbs [111, 112]. As a consequence, the mAbs 517 
glycosylation profile is considered as a CQA and must be thoroughly analyzed [113-115]. For over 10 years, num-518 
bers of analytical methods have been developed to better understand the synthesis, roles and consequences of 519 
mAbs glycosylations [111, 116, 117]. The last development of CE-MS methods highlighted the attractiveness to 520 
characterize and quantify the glycosylation heterogeneity with high accuracy and precision [107]. In 2016, a quan-521 
titative twoplex glycan analysis using heavy and light carbon stable isotopes of 2-aminobenzoic acid (2-AA) label-522 
ling have been developed to check the quality of different mAbs batches [118]. Glycosylation profiles have been 523 
detected and identified with a fluorescence detector on different cetuximab batches. Comparison with orthogonal 524 
techniques as HPLC-MS were realized using a released glycan approach. Results showed a good agreement and 525 
the reproducibility of the two methods. In 2017, Giorgetti et al. evaluated the CZE-ESI-MS method to perform 526 
relative quantitation of N-glycan species for mAbs characterization at the peptides level [119]. Validation in terms 527 
of robustness and reproducibility were demonstrated through the relative quantitation of glycosylation profiles 528 
for ten different mAbs and two biosimilar produced in different cell lines. A systematic comparison was performed 529 
with hydrophilic interaction liquid chromatography (HILIC) reference method, obtaining very similar glycosylation 530 
pattern. Some glycan differences can also be provided from a difference of linkage between two glycosylation 531 
units. Sialic acid linkages differences have been observed by Kammeijer et al. using CZE-ESI-MS [120]. Although 532 
identical fragmentation patterns obtained by collision induced dissociation (CID), authors detailed the selective 533 
analysis of α 2,3 and α 2,6 –sialylated glycopeptides with no additional sample preparation. The different migration 534 
behavior between the two moieties was found to correlate with differences of pKa values which is consistent with 535 
the selectivity of the separation. In 2018, Chen et al. worked on the glycoprofiling of the NIST mAb with a mCE-536 
MS interface [27]. Authors proposed a quick solution for intact mAb characterization with quantitative results on 537 
protein variants. They obtained a partial separation and the relative quantitation of 18 variants including some 538 
glycolytic modifications. In the last few months of 2018, Jooβ et al. described a method based on CZE coupled to 539 
drift tube ion mobility MS for the analysis of native and APTS-labeled N-glycans [121]. In their study, each individ-540 
ual glycan signal separated in CZE exhibited an unexpected high number of peaks observed in the IMS dimension. 541 
Among the possible explanations, the type of sialic acid attached to glycans has a significant impact on the IMS 542 
heat map.  543 
 544 
5.2.3. Middle-up analysis 545 
 546 
Biopharmaceutics analysis at the bottom-up level involves sample treatments as digestion protocol which is 547 
known to potentially induce some artefactual modifications of amino acids implying possible over estimation of 548 
PTMs.  To avoid or reduce these limitations, optimizations of sample preparation were developed to study mAbs 549 
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at other levels such as middle-up or intact ones. Middle-up analysis consists of a prior partial and localized mAbs 550 
digestion by the mean of specific enzymes and reduction reagents. Obtained fragments, usually larger than 10 551 
kDa, gave the opportunity to focus on specific parts of the mAbs structure with a lower difficulty than intact mol-552 
ecules. The middle-up level has been made possible due to the development of proteolytic enzymes like Strepto-553 
coccal endopeptidase (IdeS) or papain. On contrary to bottom-up level, middle-up strategies allow to enhance the 554 
sample preparation protocol by reducing the number of chemical steps and then minimizing modifications in-555 
duced by digestion. 556 
Due to the limited proteolysis of mAbs which generates significantly larger peptides as compared to classical 557 
trypsin or Lys-C digestions, different strategies of online and offline CE-MS coupling have been developed in the 558 
last ten years. Biacchi et al. detailed an offline CE-MALDI/ESI-MS method for the analysis of Fc/2 and F(ab’)2 frag-559 
ments produced from the IdeS digestion of cetuximab [122]. They concluded on the baseline separation of Fc/2 560 
lysine variants and the characterization of the N-glycosylation sites present on the mAb. In 2016, the same group 561 
deepened their study by demonstrating the separation in native conditions of three Fc/2 homo- or heterodimers 562 
depending on the presence of a C-terminal lysine [123]. The first study using an online CE-ESI-MS coupling for 563 
mAbs separation at middle-up level was described by Han et al. in 2016 [124]. Authors demonstrated the baseline 564 
separation of HC and LC after reduction of disulfide bridges as well as the complete separation of Fc/2, Fd and LC 565 
fragments after Ides digestion followed by a reduction step. Concerning IdeS digestion, they obtained in less than 566 
20 minutes, a separation of Fc/2 lysine variants and observed mass differences between control, deamidated and 567 
oxidized stressed mAbs. 568 
Very recently, two major articles were published on the multi-level characterization of diverse mAbs combining 569 
middle-up and intact strategies using CZE-ESI-MS methods. Belov and coworkers developed CZE-ESI-MS methods 570 
to study different IgG1 at the intermediate level with an IdeS digestion but no reduction step [104]. CE conditions 571 
consisted of the use of a 1-(4-iodobutyl) 4-aza-1-azoniabicyclo[2,2,2] octane iodide (M7C4I) positively coated ca-572 
pillary with a BGE composed of 50 % ethanol added to 1 % formic acid and a voltage of 20 kV. They obtained a 573 
separation of Fc/2 and F(ab)’2 fragments in less than 60 minutes, with the characterization of modifications such 574 
as oxidations and deamidations. In addition, they studied the same samples with a combination of IdeS digestion 575 
and a TCEP reduction step. They obtained separation of respectively LC, Fc/2 and Fd fragments in nearly 40 576 
minutes. Both experiments allowed to characterize different glycoforms on the Fc/2 fragments. The same year, 577 
Somsen’s team succeed in separating Fc/2 glycoforms by varying BGE [125]. Neutral LPA capillary has been em-578 
ployed due to the near zero EOF generated during the separation and to avoid protein adsorption on the capillary 579 
wall. They discussed the effect of acetic acid concentration as BGE. A complete characterization of the different 580 
Fc/2 variants has been detailed with the glycan and C-terminal Lys variability and the observation of other PTMs 581 
as deamidation.  582 
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 583 
5.2.4. Intact protein analysis 584 
 585 
Analysis of intact protein, which is considered particularly challenging, represents the absolute way of protein 586 
characterization. Indeed, due to the reduction or even the absence of sample preparation which can introduce 587 
artefactual modifications, intact protein analysis has the advantage to be more representative of the actual sam-588 
ple. However, due to the high masses and the complexity of mAbs, intact level analysis of these therapeutics is 589 
still a challenge for analytical sciences. CE-MS coupling has been described as a promising technique for the char-590 
acterization of intact proteins [126] and then has been applied particularly these last years in the field of biother-591 
apeutics [14]. In 2014, Biacchi et al. detailed the first separation of intact mAbs using an offline CZE-MALDI-MS 592 
coupling [100]. The offline property of the CE-MS coupling allows the authors to work with salt-concentrated and 593 
non-volatile BGE enabling them to obtain the separation and MS analysis of intact charge variants of trastuzumab. 594 
Unfortunately, limitation of MALDI-MS resolution for molecules up to 100 kDa did not allow the measurement of 595 
the exact mass of these charge variants. Direct CE-ESI-MS coupling then appears as a solution to avoid this limita-596 
tion. In 2016, Han et al. proposed the separation and identification of free LC contained in IgG1 reference material 597 
using CZE-ESI-MS method [124]. The same year, Ramsey’s group developed and employed a CE-nanoESI-MS mi-598 
crochip for the analysis of intact infliximab [127]. Molecular weights were determined for five charge variants 599 
separated on a 23 cm long separation channel coated with an aminopropylsilane (APS) base layer and covalent 600 
modification with polyethylene glycol (PEG). Three major species corresponding to C-terminal lysine variants plus 601 
some minor acidic and basic species have been characterized with an average resolution of 0.80. The same group 602 
used this method for the characterization of a lysine-linked ADC [128]. Authors observed the separation of five 603 
main species that differed in their respective DAR, which for each DAR displayed the same variant population 604 
observed on the unconjugated mAb. They concluded that the CE-nanoESI-MS microchip method demonstrated 605 
the possibility of accurately determine the DAR.  606 
In 2017, Belov et al. have been the first group to analyze intact mAb by online native CZE-ESI-MS [22]. Working 607 
on a sheathless CE-MS interface coupled with an orbitrap mass spectrometer and using neutral polyacrylamide 608 
coated capillary, they obtained a partial separation of intact mAbs aggregates. Native condition as 20 mM ammo-609 
nium acetate pH 8.0 allowed them to reveal predominant forms of the intact mAb, corresponding to 2X-glycosyl-610 
ated, 1X-glycosylated and dimeric structures. They also observed other molecular species of about 101 kDa, pre-611 
sumably corresponding to the mAb with the loss of 2 light chains. The dissociated light chains have been separated 612 
as monomeric and dimeric forms. In 2018, the same group worked on another mAb under denaturing conditions 613 
and using a positively charged coating capillary (M7C4I) [104]. Optimized BGE condition composed of 10% isopro-614 
panol, 0.2% formic acid allows them to report the complete glycosylation profile of the mAb. Three types of mAb 615 
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glycans populations (2X-glycosylated, 1X-glycosylated and aglycosylated forms) have been observed (Figure 5). 616 
Very soon after this paper, Haselberg et al. performed the heterogeneity assessment of intact trastuzumab and 617 
ustekinumab using sheathless CE-MS interface coupled with a Q-TOF MS instrument [125]. For the two mAbs, 618 
partial separation of charge variants has been obtained using 10% acetic acid BGE and a neutral capillary coating 619 
consisting of a hydrophobic layer to protect siloxanes from hydrolysis, and a second layer of polyacrylamide provid-620 
ing a hydrophilic surface. Each peak appeared to consist of variants mixtures with different properties depending 621 
of the nature of the mAb. The same year, a third paper about intact mAb separation using sheathless CZE-ESI-MS 622 
has been published by Giorgetti et al. [103]. Using 3% acetic acid BGE, sample buffer of 30% methanol 1% formic 623 
acid and a PEI positively coated capillary, separation of three world-wide health authorities approved mAbs (ritux-624 
imab, palivizumab and trastuzumab), have been evaluated. CZE-ESI-MS analysis of these three mAbs showed par-625 
tial separation obtained in less than 20 min allowing identification of mAbs isoforms. For each mAb, 2X-glycosyl-626 
ated and 1X-glycosylated structures have been identified and separated. Concerning basic and acidic variants, 627 
minor differences between 0 and 2 Da have been observed suggesting potential iso-Asp modification and deaN. 628 
However, mass accuracy of the mass spectrometer added to separation performances, did not allow to conclude 629 
without ambiguity on the nature of these modification.  630 
As a well-known property, MS-based methods present the main drawback to be intolerant to classical salted 631 
and non-volatile BGE reducing the possibility of optimizing CE methods. Indeed, in a comparison between refer-632 
ence CZE-UV and CZE-ESI-MS methods using different BGE, obtained electropherograms fitted well but lower res-633 
olutions were obtained for CZE-ESI-MS [103]. In 2017, Jooβ et al. described a CZE-CZE-MS method for the charac-634 
terization of intact mAbs charge variants [129]. Authors achieved interference-free, highly precise mass data (de-635 
viation less than 1 Da) of trastuzumab charge variants. The mass accuracy obtained (< ppm) were discussed re-636 
garding both measured and calculated masses. The same group confirmed the advantages of their 2D CE-MS sys-637 
tem with the development of a cIEF-CZE-MS for the characterization of intact mAbs [69]. After focusing step, the 638 
analytes were mobilized through two external detectors (UV and C4D) to select precisely analytes inside the trans-639 
fer loop and then to run the CZE dimension prior to MS detection. They established a “multiple heart-cut” ap-640 
proach considerably reducing the analysis time allowing them to perform the transfer of up to six analytes from a 641 
single cIEF run and the analysis via CZE-MS in less than 3h. Application on the MS characterization of intact mAb 642 
charge variants enabled them to detect a mass difference of approximately 2 Da between two variants. In 2018, 643 
the same group deepened the development of the 2D CE-MS coupling to identify low abundance charge variants 644 
of trastuzumab using icIEF-CZE-MS [70]. icIEF first dimension can be monitored in real-time thanks to the whole-645 
column detection. Accurate masses were attributed to deamidation, formation of succinimide or cyclisation of N-646 
terminal glutamic acid for the main acidic and basic variants. Despite the difficulty to achieve online cIEF-ESI-MS 647 
application due to CE experimental condition, Dai et al. reported a new online cIEF-ESI-MS method for mAb charge 648 
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variant analysis using an electrokinetically pumped sheath-flow nanospray ion source with pressure-assisted 649 
chemical mobilization [67]. Many critical parameters and reagents have been optimized including MS-friendly 650 
anolyte and catholyte, a glycerol enhanced sample mixture or ampholyte. Charge variant profiles of trastuzumab, 651 
bevacizumab, infliximab and cetuximab, obtained using cIEF-MS method, were corroborated by icIEF-UV analysis. 652 
Moreover, charge variants of these mAbs were characterized using the online intact MS data. More recently, the 653 
same group applied their cIEF-ESI-MS method for the in-depth characterization of cetuximab charge heterogeneity 654 
[68]. 655 
 656 
6. Conclusion 657 
Due to the inherent structural complexity of the mAbs format, a wide variety of analytical techniques, including 658 
liquid chromatography, electrophoresis and mass spectrometry have been implemented. Detailed characteriza-659 
tions of these therapeutic proteins have been obtained by these techniques to ensure the integrity of the drugs. 660 
Therefore, the physicochemical phenomenon involved in CE separation demonstrated in numerous applications a 661 
unique benefit for mAbs analysis. Conventional CE separation modes like CZE, CE-SDS or (i)cIEF are particularly 662 
relevant to characterize mAbs size and charge variants thanks to CE intrinsic features which provide efficient and 663 
highly-resolutive separations. Furthermore, the different inter-laboratory studies support unambiguously the con-664 
fidence of the analysis in addition to the robustness provided by the CE-based analytical methods. As a conse-665 
quence, CE has gradually become one of the reference technique in the biopharmaceutical industry to assess 666 
purity and stability of mAbs. Concomitantly, CE-MS hyphenation was implemented and demonstrated to be rele-667 
vant to access precious structural information like amino acid sequences, glycosylations, PTMs and higher-order 668 
structures.  669 
In the most recent period, the development of analytical methodologies involving CE separation has not dimin-670 
ished, which is emphasized by the significant number of articles discussed throughout the present review. Also, it 671 
is important to note that each CE separation mode is currently explored for the development of methods dedi-672 
cated to the characterization of mAbs and their related formats. Such interest is indeed attributed to an improved 673 
understanding of the charge based selectivity of the electrophoretic separation in the case of mAbs, which showed 674 
to be relevant to distinguish several types of micro-heterogeneities. In addition, the introduction of innovative 675 
molecules based on the mAbs format like ADCs contributes to the dynamic of CE method development.  676 
The implementation of CE-ESI-MS has also benefiting further from various instrumental progresses. Regarding 677 
that aspect, the recent emergence of 2D CE-MS represents a significant breakthrough. Indeed, 2D CE-MS enables 678 
to potentially improve separation and peak capacity in a similar manner as 2D liquid chromatography. The intro-679 
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duction of microfluidic technologies has also exhibited the possibility to achieve short-time analyses while main-680 
taining a high resolution due to the reduction of diffusion effects, for instance to perform a high-throughput 681 
screening of mAbs and ADCs.  682 
Future prospects regarding CE based analysis of mAbs and their associated formats suggest CE-MS hold the most 683 
important potential due to the complete orthogonality of both techniques and the performances of current gen-684 
eration of high resolution MS instruments. Also, by performing CZE using a MS compatible BGE over the second 685 
dimension, 2D CE-MS enables to perform separation mode previously incompatible with MS coupling like CE-SDS 686 
or cIEF over the first dimension. That aspect of 2D CE-MS is particularly promising because it enriches in a drastic 687 
manner the applicability of CE-MS, therefore further developments is excepted in that direction in the near future. 688 
For instance, it is possible to envisage the use of specific CE analysis like affinity CE. The application of affinity CE 689 
in conjunction with MS is particularly appealing for the characterization of mAbs. During their lifetime, mAbs are 690 
interacting with targeted antigens in addition to several types proteins which influence their effector functions 691 
and/or pharmacological properties. Thus, by distinguishing protein-protein/protein-ligand complexes and deter-692 
mine affinity constants using their respective electrophoretic mobilities, it could be possible to correlate structural 693 
modifications with mAbs affinity opening the path to structure-function analysis. The development of affinity CE-694 
MS experiments adapted to mAbs represents a major challenge however the introduction of 2D CE-MS clearly 695 
reshuffles the cards on that aspect. Finally, because native MS analysis is often limited by the absence of separa-696 
tion before the MS analysis, the development of CE-MS analysis performed could improve significantly the sensi-697 
tivity and widening the applicability of native MS. This could be applied especially for the analysis of complex 698 
mixtures while maintaining therapeutic mAbs is a state as close as possible to the protein administrated to the 699 
patient. 700 
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Caption 1105 
 1106 
Fig. 1. Electropherograms of the mAb-A initial sample (lower trace) and degradation sample (upper trace) ob-1107 
tained by CE-SDS (a) reduced and (b) non-reduced conditions. The internal standard peak, light chain peak, heavy 1108 
chain peak, monomer peak, and increased peaks are indicated. Especially, the increased peak close to the internal 1109 
standard is the focus of this study. Reprinted from [35]. Copyright (2017) Elsevier. 1110 
 1111 
Fig. 2. Online CE-LIF-MS analysis of Teal™-labeled NISTmAb released N-glycans. LIF and MS base peak elec-1112 
tropherogram (m/z 620-1,800) of Teal-NISTmAb glycans using ammonium hydroxide based BGE. Reprinted from 1113 
[28]. Copyright (2017) Wiley. 1114 
 1115 
Fig. 3. Imaged capillary isoelectric focusing for profile of the isolated charge variants, the biosimilar product and 1116 
Avastin. Reprinted from [76]. 1117 
 1118 
Fig. 4. Charge profiles of a mixture comprising valid bevacizumab, trastuzumab and rituximab solutions (blue 1119 
trace) and expired solutions (orange trace). Reprinted from [87]. Copyright (2018) Wiley 1120 
 1121 
Fig. 5. Deconvolution spectrums showing major glycosylation states of the intact mAb. Quantitative ratios of 1122 
each population of the mAb (2X-glycosylated, 1X-glycosylated, aglycosylated) are specified. Reprinted from [104]. 1123 
Copyright (2018) Wiley. 1124 
 1125 
 1126 
 1127 
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Table 1. Application and CE methods for the analysis of IgG, biosimilars, Fc-fusion proteins and ADCs in the years 2016-2018 
Abbreviation: PBS phosphate buffer saline; EACA ε-amino caproic acid; TETA triethylenetetramine; BFS bare fused silica; LPA linear polyacrylamide; PVA polyvinyl 
alcohol; HPMC hydroxypropyl-methyl cellulose; HPC hydroxypropyl cellulose; FC fluorocarbon; PB polybren; DS dextran sulfate; PEO Polyethylene oxide; APS 
aminopropylsilane; APTES aminopropyltriethoxysilane 
 
CE Mode 
 
Detection Sample Application BGE Cap. coating Reference 
CE-SDS 
mGE 
UV 220 nm mAb Size heterogeneity of reduced 
mAb 
SDS gel separation 
buffer 
BFS  [39] 
CE-SDS UV 220 nm Ado-trastuzumab em-
tansine & biosimilar 
Biosimilarity assessment, size het-
erogenetiy of intact and reduced 
mAb 
SDS gel separation 
buffer 
BFS [45] 
CE-SDS UV 220 nm IgG1 Disulfide bond reduction SDS-MW gel buffer BFS [30] 
CE-SDS UV 220 nm IgGs Purity and stability assessment SDS-MW gel buffer BFS [31] 
mGE  mAb Intra and extracellular evaluation 
of LC:HC ratio 
  [130] 
CE-SDS LIF 488 nm 520 nm IgG High-throughput N-glycan analysis NCHO Carbohydrate  
Separation Buffer 
NCHO separa-
tion capillary 
[25] 
CE-SDS LIF IgG N-glycan analysis 1% PEO in 25 mM lith-
ium acetate (pH 4.75) 
NCHO separa-
tion capillary 
[26] 
mGE Indirect LIF bsAb Size heterogeneity of reduced and 
intact mAb 
HT Protein Express 
Sample Buffer 
 [131] 
CE-SDS UV 220 nm Recombinant IgG1 Size heterogeneity of intact and 
reduced mAb 
SDS-MW gel buffer BFS [38] 
CE-SDS LIF 488 nm 520 nm Ranibizumab and bio-
similar (labeled) 
Biosimilarity assessment, size het-
erogeneity of intact mAb 
0,1 M Tris-HCl/5% SDS 
pH 8 
BFS [33] 
CE-SDS LIF 488 nm 520 nm mAbs Glycan profiling 89 mM aqueous Tris-
boric solution pH 8.64 
PEGDMA or 
PAA 
[51] 
CE-SDS UV 220 nm mAb A Size heterogeneity of reduced and 
intact mAb 
SDS gel separation 
buffer (AB Sciex) 
BFS [35] 
CE-SDS UV 220 nm Recombinant IgG1 Quantitation of impurety from de-
graded mAb 
SDS sieving gel buffer 
(Beckman) 
BFS [36] 
CE-SDS UV 220 nm IgG1 Size heterogeneity of reduced and 
intact mAb 
SDS-MW gel buffer BFS [38] 
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CE-SDS UV 220 nm Tocilizumab & biosimi-
lar 
Biosimilarity assessment, size het-
erogeneity of reduced and intact 
mAb 
SDS sieving gel buffer 
(Beckman) 
BFS [34] 
CE-SDS UV 220 nm NIST mAb Fab fragment characterization SDS-MW gel buffer BFS [132] 
CE-SDS LIF 488 nm 520 nm hIgG N-glycan characterization 1% HPC (w/v), 1% HEC 
(w/v), 80 mM MES,40 
mM TRIS 
PVA [23] 
CE-SDS LIF 325 nm 405 nm Rituximab, Trastu-
zumab & Beveca-
zumab 
N-glycan analysis 100 mM Tris-borate 
buffer (pH 8.3) 5% PEG 
DB-1 [29] 
CE-SDS  Lys-conjugated ADC Size heterogeneity of reduced and 
intact ADC 
  [43] 
CE-SDS LIF hIgG N-glycan characterization of irra-
diated mAb 
N-CHO BFS [50] 
CE-SDS LIF NISTmAb RM 8671 Glycan profiling POP 7 polymer  [27] 
CE-SDS-
LIF-MS 
LIF 488 nm 520 
nm, LTQ-Orbitrap 
XL 
NISTmAb RM 8671 Glycan analysis NH4OH or AcNH4 BFS [28] 
CE-SDS 
mGE 
LIF 488 nm 520 nm Fc fragment of adali-
mumab 
Glycan absolute quantification HR-NCHO BFS [52] 
icIEF UV 280 nm mAb-DM1 ADCs Drug Load Distribution and DAR 
determination 
 FC [82] 
icIEF UV 280 nm 3 recombinant hmAb Charge heterogeneity of intact 
mAb, comparison with FFE 
Amph : 3-10 Anol 80 
mM H3PO4 Cath : 100 
mM NaOH 
Coated capil-
lary from Con-
vergent Biosci-
ence 
[78] 
cIEF UV 280 nm IgG1 Charge heterogeneity, structural 
characterization 
Amph : 3-10 Anol 200 
mM H3PO4 Cath : 300 
mM NaOH 
eCAP™ Neutral [30] 
icIEF UV 280 nm Rituximab & biosimilar Charge heterogeneity of intact 
mAb and mAb's fragments 
Amph : 2% 5-8 & 8-
10.5 Anol : 0,08 M 
H3PO4 Cath 0.1 M 
FC [75] 
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NaOH + 0,1% MC in 
both 
icIEF UV 280 nm IgG1 Charge heterogeneity, purity as-
sessment 
Amph : 3-10 : 8-10.5 
(1:1) 
 [76] 
icIEF UV 280 nm 23 marketed mAbs Charge heterogeneity, pI determi-
nation 
Amph : 3-10 Anol : 80 
mM H3PO4 Cath : 100 
mM NaOH + 0,1% MC 
in both 
FC [73] 
icIEF UV 280 nm Tocilizumab & biosimi-
lar 
Charge heterogeneity of intact 
mAb 
Amph : 3-10  [34] 
icIEF UV 280 nm Antibody A Charge heterogeneity of native 
mAb 
Amph : 3-10  [77] 
icIEF UV 280 nm IgG1, IgG2 & IgG4 Interlaboratory study 
Charge heterogeneity of intact 
mAb, purity assessment 
Amph : 3-10 + 1%MC FC [72] 
icIEF UV 280 nm IgG1 Charge heterogeneity of intact 
mAb 
Anol : acid Cath : base  [74] 
cIEF-MS 
icIEF-UV 
UV 280 nm &TOF Infliximab, Trastu-
zumab, Bevacizumab 
& Cetuximab 
Charge heterogeneity of intact 
mAb 
cIEF-MS : Amph : 3-10 
Anol : 1% formic acid 
Cath : 0,2 N NH4OH + 
15 % glycerol in both 
iCIEF-UV : Amph : 3-10 
Anol : 80 mM H3PO4 
Cath : NaOH + 0,1% 
MC in both 
cIEF-MS : Neu-
tral coating 
PS1 iCIEF-UV : 
FC 
[67] 
cIEF 
CZE 
UV 280 nm NISTmAb RM 8671 Charge heterogeneity Amph : 3-10 : 8-10.5 
(1:3) Anol 200 mM 
H3PO4 Cath : 300 mM 
NaOH 
Neutral coa-
ting (Sciex PN 
477441) 
[79] 
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CZE 
icIEF 
UV 214 nm mAbs Characterization of mAb variants 40 mM EACA; 2 mM 
TETA pH 6.0 
HPMC [59] 
CZE UV 214 nm mAb ADC Method validation 380 mM EACA, 1.9 
mM TETA, pH 5.7 
0.05% HPMC 
HPMC [84] 
CZE  mAb Method development for mAbs 
quality 
50 mM EACA; 1 mM 
TETA pH 4.1 
HPMC [95] 
CZE UV 280 nm Bevacizumab and bio-
simlar 
Characterization of mAb charge 
variants 
500 mM EACA BFS [96] 
CZE 214 nm mAb Characterization of mAb isoforms 200 mM EACA; 30 mM 
lithium acetate 
HPMC [94] 
CZE 
CE-SDS 
 Human IgG Glycosylation profiling 25 mM NH4Ac, pH 
4,75 
PVA [23] 
CZE 
CE-SDS 
UV 214 nm Ranibizumab; Ra-
zumab (biosimilar) 
Serine to Asparagine sequence 
variation 
400 mM EACA; 2 mM 
TETA pH 5.7 
BFS [33] 
CZE UV 280 nm mAb; ADC Charge variants and disulfide iso-
mers of mAbs and ADCs 
400 mM EACA; 2 mM 
TETA pH 5.7 
HPMC [89] 
CZE UV 214 nm mAbs Charge heterogeneity of mAbs 40 mM EACA; 2 mM 
TETA pH 6.0 
HPC; HPMC [97] 
CZE UV 280 nm Cetuximab, Trastu-
zumab, Rituximab 
Characterization of mAb variants 50 mM Phosphate 
buffer 
Fibrin [88] 
CZE UV 214 nm 17 marketed mAbs Characterization of mAb variants 200 mM BisTris pH 7.0 PEO; HPMC [87] 
CZE UV 280 nm mAbs In-line tryptic digestion of mAbs 
automation 
25 mM EACA; citric 
acid pH 5.0 
PEO [90] 
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CZE UV 214 nm NISTmAb NISTmAb homogeneity value as-
signment and stability 
400 mM EACA; 2 mM 
TETA pH 5.7; 0.03% 
Tween 20 
HPMC [32] 
CZE UV 214 nm NISTmAb Charge heterogeneity of mAbs 400 mM EACA; 2 mM 
TETA pH 5.7; 0.03% 
Tween 20 
HPMC [133] 
mCE-ESI-
MS 
ESI-TOF-MS IgG1, IgG2, ADC, Inflixi-
mab 
Characterization of mAb variants 100 mM PBS + 10 g/L 
NHS-PEG 
APS [127] 
CZE-MS MALDI-TOF-MS Cetuximab Fc/2 dimers characterization Inlet vial: 200 mM 
EACA/25 mM C2H7NO2                
Outlet vial:   25 mM 
C2H7NO2 
HPC [123] 
CZE-MS ESI-QTOF-MS/MS Trastuzumab Asparagine deamidation and iso 
Aspartic acid isomerization 
10% CH3CO2H BFS [108] 
CZE-MS ESI-TOF-MS IgG1 Charge heterogeneity of reduced 
mAb                     Middle up analy-
sis 
10% - 30% CH3CO2H   
SL: 50% CH4O/0.5% 
COOH 
LPA [124] 
mCE-ESI-
MS 
ESI-QTOF-MS ADC Characterization of intact ADC 10% C3H8O + 0.2% 
CH3CO2H 
PEG, APS [128] 
CZE-MS ESI-QTOF-MS/MS Brentuximab vedotin 
ADC 
Intact, middle-up and bottom-up 
characterization 
10% CH3CO2H BFS [109] 
CZE-MS ESI-QTOF-MS/MS Cetuximab Glycan analysis 25 mM C2H7NO2 PVA [118] 
CZE-MS ESI-Orbitrap-
MS/MS 
standards proteins               
E. Coli ribosomal pro-
teins                                  
trastuzumab 
Proteins, protein complexes and 
organellar proteomes analysis 
40 mM C2H7NO2 BFS                                               
PA 
[22] 
CZE-MS MALDI-TOF-MS Cetuximab MAb Fc/2 charge variants analysis Inlet vial: 200 mM 
EACA/25 mM C2H7NO2                
Outlet vial:   25 mM 
C2H7NO2 
HPC [21] 
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CZE-MS ESI-Orbitrap-
MS/MS 
ADC Peptide mapping of therapeutic 
proteins 
20% CH3CO2H          
15% DMA 1% m-nitro-
benzyl alcohol 
LPA [110] 
CZE-MS ESI-Orbitrap-
MS/MS 
mAb Improvment peptide mapping of 
therapeutic proteins 
20% CH3CO2H/15% 
DMA  or DMF 
LPA [134] 
CZE-MS ESI-QTOF-MS/MS Rituximab; pali-
vizumab; natalizumab; 
nivolumab; trastu-
zumab; panitumumab; 
adalimumab; inflixi-
mab-remicade; inflixi-
mab-remsima; inflixi-
mab inflectra 
Mabs N-glycosylation profiling 10% CH3CO2H BFS [119] 
CZE-MS ESI-QTOF-MS/MS Human polyclonal IgG                                 
recombinant monoclo-
nal IgG1 
Sialic acid linkage differenciation 
of glycopeptides 
10% CH3CO2H BFS [120] 
CZE-MS ESI-QTOF-MS/MS IgG1 Eliminate SDS interferences in an-
tibody analysis 
1 M CH3CO2H                        
SL:  C3H8O/0.2% CH2O2 
(50:50) 
PVA                                     
PB 
[135]
CZE-MS ESI-Orbitrap-
MS/MS 
mAb Analysis of host cell impurities in 
mAbs 
2 M CH3CO2H                        
SL:  10% CH3OH/0.5% 
CH2O2 
LPA  [136] 
CZE-MS ESI-Orbitrap-
MS/MS 
IgG1 Middle-down and intact mAb pro-
teoform characterization 
50% CH3OH/1% CH2O2                                  
10% C3H8O/0.2% 
CH2O2 
M7C4I                                 
PA 
[104]
mCE-ESI-
MS 
ESI-Orbitrap-
MS/MS 
NIST mAb NIST mAb proteoforms and gly-
coforms characterization 
0.2% CH3CO2H/10% 
C3H8O 
APS [27] 
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cIEF-MS ESI-TOF-MS Infliximab, trastu-
zumab, cetuximab, be-
vacizumab 
Intact mAb charge variants analy-
sis 
Amph: 3-10 + 5-20% 
glycerol                  
Anol: 1% CH2O2 + 15% 
glycerol           Cath: 
0.2% NH4OH + 15% 
glycerol 
Neutral PS1 [67] 
cIEF-MS ESI-TOF-MS Cetuximab Intact and middle-up characteriza-
tion 
Amph: 3-10 + 5-20% 
glycerol                  
Anol: 1% CH2O2 + 15% 
glycerol           Cath: 
0.2% NH4OH + 15% 
glycerol 
Neutral PS1 [68] 
CZE-MS ESI-QTOF-MS Infliximab, trastu-
zumab, ustekinumab 
Heretogeneity assessment of anti-
body derived therapeutics 
10% CH3CO2H Neutral [125] 
CZE-MS ESI-QTOF-MS Trastuzumab, rituxi-
mab, palivizumab 
Intact mAb charge variants analy-
sis 
3% CH3CO2H PEI [103] 
CZE-MS ESI-Orbitrap-
MS/MS 
mAb Glycosylation profiling C2H7NO2                         
SL: 10 mM 
C2H7NO2/C2H3N 
(20/80) 
BFS [28] 
CZE-MS IMS-Q-TOF-MS mAb Glycosylation profiling 0.1 M EACA, 0.5 M 
NH3 solved in MeOH/ 
H2O 1:1 
BFS [121] 
cIEF-CZE-
MS 
UV; ESI Q-TOF-MS Deglycosylated mAb Charge heterogeneity cIEF :Amph : 3-10 ou 
6-8 Anol H3PO4 Cath 
NaOH CZE : 0,2 M 
HCOOH 
PVA both [69] 
CZE-CZE-
MS 
UV 214 nm ; ESI Q-
TOF-MS 
Trastuzumab Intact mAb charge variants CZE 1 : 380 mM EACA, 
1,9 mM TEA and 
0,05% w/w HPMC (pH 
CZE 1 : BFS CZE 
2 : PVA 
[129] 
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5.7) CZE 2 : 2 M acetic 
acid 
cIEF-CZE-
MS 
UV 280 nm; ESI-Q-
TOF-MS 
Trastuzumab Charge heterogeneity icIEF : Amph : AESlyte, 
Anol : 80 mM H3PO4, 
Cath : 80 mM NaOH 
0.1 % MC both  CZE : 
1M acetic acid 
PVA both [70] 
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Fig. 1. Electropherograms of the mAb-A initial sample (lower trace) and degradation sample (upper trace) obtained by CE-SDS (a) reduced and (b) non-reduced 
conditions. The internal standard peak, light chain peak, heavy chain peak, monomer peak, and increased peaks are indicated. Especially, the increased peak 
close to the internal standard is the focus of this study. Reprinted from [35]. Copyright (2017) Elsevier. 
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Fig. 2. Online CE-LIF-MS analysis of Teal™-labeled NISTmAb released N-glycans. LIF and MS base peak electropherogram (m/z 620-1,800) of Teal-NISTmAb 
glycans using ammonium hydroxide based BGE. Reprinted from [28]. Copyright (2017) Wiley. 
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Fig. 3. Imaged capillary isoelectric focusing for profile of the isolated charge variants, the biosimilar product and Avastin. Reprinted from [76]. 
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Fig. 4. Charge profiles of a mixture comprising valid bevacizumab, trastuzumab and rituximab solutions (blue trace) and expired solutions (orange trace). 
Reprinted from [87]. Copyright (2018) Wiley 
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Fig. 5. Deconvolution spectrums showing major glycosylation states of the intact mAb. Quantitative ratios of each population of the mAb (2X-glycosylated, 1X-
glycosylated, aglycosylated) are specified. Reprinted from [104]. Copyright (2018) Wiley. 
 
 
